Under construction – not a live service
Sign in
Taking people in ChinaPhase 3

Tests enicepatide in adults with obesity or overweight, with or without diabetes

Tests enicepatide in adults with obesity or overweight, with or without diabetes.

Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes

Key facts

Where
Beijing, Changchun, Hefei, Herbin, Huai'an, Huzhou, Jinan, Langfang, Luoyang, Nanjing, Ningbo, Shanghai, Shenyang, Shijiazhuang, Xianyang, Zhengzhou, and Zibo, ChinaSee the 21 sites
Phase
Phase 3

Where in China

  • Peking University People's HospitalBeijing, ChinaTaking people
  • The Second Hospital of Jilin UniversityChangchun, ChinaTaking people
  • The Second Affiliated Hospital Of Anhui Medical UniversityHefei, ChinaTaking people
  • The Fourth Affiliated Hospital of Harbin Medical UniversityHerbin, ChinaTaking people
  • Huai'an First People's HospitalHuai'an, ChinaTaking people
  • Huzhou Central HospitalHuzhou, ChinaTaking people
  • Jinan Central HospitalJinan, ChinaTaking people
  • Hebei Petro China Central HospitalLangfang, ChinaTaking people
  • Luoyang Third People's HospitalLuoyang, ChinaTaking people
  • The Affiliated Jiangning Hospital of Nanjing Medical UniversityNanjing, ChinaTaking people
  • The First Affiliated Hospital of Ningbo University(Ningbo First Hospital)Ningbo, ChinaTaking people
  • Shanghai East HospitalShanghai, ChinaTaking people
  • Shanghai Fifth People's Hospital Affiliated to Fudan UniversityShanghai, ChinaTaking people
  • Shanghai Tenth People's HospitalShanghai, ChinaTaking people
  • Tongren Hospital, Affiliated to Shanghai Jiao Tong University School of MedicineShanghai, ChinaTaking people
  • Shenyang Fifth People HospitalShenyang, ChinaTaking people
  • The People's Hospital of Liaoning ProvinceShenyang, ChinaTaking people
  • Hebei Medical University - The Second HospitalShijiazhuang, ChinaTaking people
  • Yan'an University Xianyang HospitalXianyang, ChinaTaking people
  • The Second Affiliated Hospital of Zhengzhou UniversityZhengzhou, ChinaTaking people
  • Zibo Municipal HospitalZibo, ChinaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Hoffmann-La Roche
Trial code
NCT07670416
Record updated
5 November 2026
Original description
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight management, as an adjunct to a reduced-calorie diet and increased physical activity in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity, and in participants with T2DM who have obesity or overweight.Read full original descriptionShow less

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 in Adult Chinese Patients With Obesity or Overweight, With or Without Type 2 Diabetes Mellitus

The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight management, as an adjunct to a reduced-calorie diet and increased physical activity in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity, and in participants with T2DM who have obesity or overweight.

Inclusion: Body mass index (BMI) ≥24.0 kilograms per meter squared (kg/m\^2) for participants with type 2 diabetes mellitus (T2DM); BMI ≥28.0 kg/m\^2 or BMI ≥24.0 and <28.0 kg/m\^2 and diagnosed with at least one weight-related comorbidity (prediabetes, hypertension, dyslipidemia, fatty liver, obstructive sleep apnea, or weight-related cardiovascular disease) for participants without T2DM; Agreement to adhere to the contraception requirements.

Exclusion: Any planned major medical procedure or surgery during the study; Treatment with any approved or investigational GLP-1-RA-based therapy within 6 months prior to randomization; Treatment with other investigational therapy within 3 months prior to randomization or less than 5 elimination half-lives prior to randomization, whichever is longer; History of Type 1 diabetes mellitus (T1DM); Obesity induced by other endocrinologic disorders; History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder; Any lifetime history of suicide attempt; History of acute or chronic pancreatitis or clinically significant gallbladder disease; Known allergy to any component of the study drug formulation or any other condition that is a contraindication to GLP-1 RAs or GLP-1/GIP RAs; History of any hematologic conditions that may interfere with HbA1c measurement.

ClinicalTrials.gov NCT07670416